Plexxikon
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
91 Bolivar Dr Unit A, Berkeley, Californ...Phone Number
(510) 647-4000Website
www.plexxikon.comRevenue
$20.4 MillionIndustry
About Plexxikon
Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's drug Zelboraf® (vemurafenib/PLX4032) was approved by the FDA in 2011, and Turalio® (pexidartinib/PLX3397) was approved by the FDA in 2019. Plexxikon is developing a portfolio of preclinical and clinical-stage compounds to address significant unmet medical needs in oncology and other therapeutic areas. Plexxikon's Scaffold-Based Drug Discovery platform integrates multiple state-of-the-art technologies, including the use of X-ray crystallography as an early screening tool that provides a significant advantage over other drug discovery approaches.Explore more
SIC Code 28,283NAICS Code 32,325Show morePlexxikon Org Chart
Plexxikon Tech Stack
A closer look at the technologies used by Plexxikon
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Plexxikon
Sign Up For FreeTo access detailed company insights
Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's drug Zelboraf® (vemurafenib/PLX4032) was approved by the FDA in 2011, and Turalio® (pexidartinib/PLX3397) was approved by the FDA in 2019. Plexx... Read More